NGL Fine-Chem Limited (NSE: NGLFINE) is a Healthcare company,
ranked #2,231 of 6,774 companies globally and #1,484 of 2,400 in India on PositoAI,
with a Positivity Score of 21,742.
Its market capitalisation is ₹1,635.01 Cr, P/E ratio is 28.6 and P/B ratio is 4.97.
It currently has 1 active red flag (PosiRed) and no yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →
NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxacin, maropitant citrate monohydrate, nitroscanate, nitroxynil, oclacitinib maleate, oxfendazole, parvaquone, permethrin, phenazone, ponazuril, praziquantel, ractopamine HCL, rafoxanide, ricobendazole, r-praziquantel, sarolaner, s-methoprene, toldimfos sodium, toltrazuril, triclabendazole, xylazine base, xylazine HCl, and zilpaterol. It also provides anthelmintics, antiprotozoals, ectoparasiticides, phosphorus supplements, coccidiostats, and non-steroidal anti-inflammatory drugs. In addition, the company offers atovaquone, nitazoxanide, and praziquantel for anti malarial, anti diarrheal, and anthelmintic therapeutic categories. Further, it provides specialty chemicals, such as meglumine, n-ethyl-d-glucamine, n-octyl-d-glucamine, 1,4,7-trimethyl-1,4,7-triazonane, and Mn-MeTACN. It serves companies engages in manufacturing custom pharmaceuticals. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
P/B Ratio4.97
P/E Ratio28.6
D/E Ratio0.37
ROE (calculated)17.37%
Owes vs Owns ?0.40× Low₹0.40 owed for every ₹1 it owns · balance sheet Mar 2026
NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base,…
What is NGL Fine-Chem Limited's P/E and P/B ratio?
NGL Fine-Chem Limited has a P/E ratio of 28.6 and a P/B ratio of 4.97.
What is NGL Fine-Chem Limited's debt-to-equity ratio?
NGL Fine-Chem Limited has a debt-to-equity ratio of 0.37.
How much does NGL Fine-Chem Limited owe compared with what it owns?
NGL Fine-Chem Limited owes ₹0.40 for every ₹1 it owns (balance sheet Mar 2026), which is low.
What is NGL Fine-Chem Limited's Positivity rank?
NGL Fine-Chem Limited is ranked #2,231 of 6,774 companies globally and #1,484 of 2,400 in India on PositoAI, with a Positivity Score of 21,742.
Does NGL Fine-Chem Limited have any SEBI orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Yes. NGL Fine-Chem Limited has 1 active red flag (PosiRed) on record: SEBI order: Exemption Order (dated 09 Oct 2026). It has no yellow flags.
Where can I read the latest news about NGL Fine-Chem Limited?
Recent headlines about NGL Fine-Chem Limited from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does NGL Fine-Chem Limited have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of NGL Fine-Chem Limited's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.
0 / 1000
🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.
Disclaimer —
PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.